Latest Articles

Publication Date
All News Scientific
Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors - Frontiers

Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors Frontiers

Published: Dec. 10, 2024, 4:36 p.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - BioSpace

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer BioSpace

Published: Dec. 10, 2024, 12:23 p.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - Yahoo Finance

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer Yahoo Finance

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer StockTitan

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
Endometrial Cancer Market: Opportunities, Challenges, - openPR

Endometrial Cancer Market: Opportunities, Challenges, openPR

Published: Dec. 10, 2024, 7:16 a.m.
Read Full Article
GSK Korea expands indication for Jemperli in endometrial cancer treatment - KBR

GSK Korea expands indication for Jemperli in endometrial cancer treatment KBR

Published: Dec. 10, 2024, 3:13 a.m.
Read Full Article
The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer - Targeted Oncology

The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer Targeted Oncology

Published: Dec. 8, 2024, 5 p.m.
Read Full Article
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - BioSpace

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer BioSpace

Published: Dec. 6, 2024, 8:22 a.m.
Read Full Article
Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer OncLive

Published: Dec. 5, 2024, 7:04 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!